[go: up one dir, main page]

ATE392620T1 - Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen - Google Patents

Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen

Info

Publication number
ATE392620T1
ATE392620T1 AT01992896T AT01992896T ATE392620T1 AT E392620 T1 ATE392620 T1 AT E392620T1 AT 01992896 T AT01992896 T AT 01992896T AT 01992896 T AT01992896 T AT 01992896T AT E392620 T1 ATE392620 T1 AT E392620T1
Authority
AT
Austria
Prior art keywords
app
patological
changes
detection means
protein app
Prior art date
Application number
AT01992896T
Other languages
English (en)
Inventor
Andre Delacourte
Nicolas Sergeant
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE392620T1 publication Critical patent/ATE392620T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01992896T 2000-11-03 2001-11-05 Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen ATE392620T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0014143A FR2816411B1 (fr) 2000-11-03 2000-11-03 Moyens de detection de la transformation pathologique de la proteine app et leurs applications

Publications (1)

Publication Number Publication Date
ATE392620T1 true ATE392620T1 (de) 2008-05-15

Family

ID=8856055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01992896T ATE392620T1 (de) 2000-11-03 2001-11-05 Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen

Country Status (13)

Country Link
US (1) US7723117B2 (de)
EP (1) EP1330656B1 (de)
JP (1) JP4294953B2 (de)
AT (1) ATE392620T1 (de)
AU (2) AU2374302A (de)
CA (1) CA2427604A1 (de)
CY (1) CY1108182T1 (de)
DE (1) DE60133661T2 (de)
DK (1) DK1330656T3 (de)
ES (1) ES2305126T3 (de)
FR (1) FR2816411B1 (de)
PT (1) PT1330656E (de)
WO (1) WO2002037118A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US7598049B2 (en) * 2003-11-19 2009-10-06 Satoris, Inc. Methods for diagnosis of Alzheimer's Disease in blood samples
CA2585983C (en) 2004-11-10 2014-03-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
DE202007015863U1 (de) * 2007-11-12 2009-03-26 Melitta Haushaltsprodukte Gmbh & Co. Kommanditgesellschaft Filterpapiereinsatz
CA2712303C (en) 2008-01-18 2015-03-31 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
JP5719852B2 (ja) 2009-12-16 2015-05-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ７−クロロ−キノリン−４−アミン化合物、ならびにアミロイド斑の形成を含み、及び／又はａｐｐの代謝機能障害が生じる疾患の予防又は治療のためのそれらの使用
BR112013001754A2 (pt) 2010-07-23 2016-05-31 Harvard College método para detectar marcas de doença ou condições em fluídos corpóreos
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
WO2012012694A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2596134B1 (de) 2010-07-23 2020-04-08 President and Fellows of Harvard College Verfahren zur erkennung von erkrankungen oder leiden mit phagozytischen zellen
US20130096552A1 (en) * 2011-10-14 2013-04-18 Christopher L. Brace Hydrodissection Material with Reduced Migration
SG11201408383SA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
WO2014164366A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting cancer
US9987233B2 (en) 2013-03-21 2018-06-05 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
MX2018005035A (es) 2015-10-27 2018-09-06 Eupraxia Pharmaceuticals Inc Formulaciones de liberacion sostenida de anestesicos locales.
US11397188B2 (en) * 2017-03-30 2022-07-26 Board Of Regents, The University Of Texas System Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
AU8215391A (en) * 1990-06-29 1992-01-23 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
AU5135393A (en) * 1992-09-21 1994-04-12 United States Of America, As Represented By The Secretary, Department Of Health And Human Services A method of screening compounds and methods for treating alzheimer's disease
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)

Also Published As

Publication number Publication date
JP4294953B2 (ja) 2009-07-15
EP1330656A1 (de) 2003-07-30
US7723117B2 (en) 2010-05-25
CA2427604A1 (fr) 2002-05-10
FR2816411A1 (fr) 2002-05-10
JP2004522940A (ja) 2004-07-29
ES2305126T3 (es) 2008-11-01
WO2002037118A1 (fr) 2002-05-10
DE60133661D1 (de) 2008-05-29
AU2002223743B2 (en) 2007-01-11
FR2816411B1 (fr) 2003-07-04
CY1108182T1 (el) 2014-02-12
AU2374302A (en) 2002-05-15
DE60133661T2 (de) 2009-05-28
US20070026527A1 (en) 2007-02-01
PT1330656E (pt) 2008-07-24
DK1330656T3 (da) 2008-08-11
EP1330656B1 (de) 2008-04-16

Similar Documents

Publication Publication Date Title
ATE392620T1 (de) Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
DE69933661D1 (de) Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
DK2146209T3 (da) Neurodegenerative markører for Alzheimer's sygdom
NO973444L (no) Fremgangsmåter og forbindelser for magnetrelaksometrisk påvisning av analytter, samt anvendelse av slike
MA29836B1 (fr) Proteines de fusion avec l'albumine
AU2003253784A8 (en) Peptides from the e2, e6 and e7 proteins of human papillomaviruses 16 and 18 for detecting and/or diagnosing cervical and other cancers
ATE401342T1 (de) Verfahren und materialien zum nachweis und zur messung von durch freie radikale verursachten schäden
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
EP1680666A4 (de) Nachweisen von menschlichen antitherapeutischen antikörpern
BR0314155A (pt) Métodos para diagnosticar câncer cervical
DE69535901D1 (de) Proteinkinase npk-110
DK1257829T3 (da) Komplementationsassay der vurderer proteinoplöselighed og -foldning
EP1487854A4 (de) Neue isoformen des gefässendothel-zellwachstumshemmers
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
WO2005041631A3 (en) Endotheliase-1 ligands
FR2888937B1 (fr) Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes
WO2001063293A8 (en) Diagnosis and treatment of schizophrenia
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
WO2001069261A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
FR2852096B1 (fr) Instrument indicateur de direction permettant d'indiquer l'heure et la direction de la mecque.
DE60334200D1 (de) Verfahren zur messung von neprilysinaktivität
WO2006089422A8 (en) Protein and its use in diagnosing alzheimer's disease
ATE511643T1 (de) Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1330656

Country of ref document: EP